甲状腺功能减退与乳腺癌发病相关性的 Meta分析

方媛 1 ，李艳霞 2 ，张坚 3 ，孙晶 3 ，田利民 4

1.甘肃中医药大学临床医学院，甘肃 兰州，730000；2.河北省荣军医院功能检查科，河北 保定，071000； 3.宁夏医科大学临床医学院，宁夏 银川，750004；4.甘肃省人民医院内分泌科，甘肃 兰州,730000

浏览次数：123次 下载次数：260次

摘要：

目的 系统评价甲状腺功能减退（甲减）与乳腺癌发病率的相关性。方法 计算机检索 PubMed、CNKI、CBM 等数据库，检索时限截至 2017年10月，搜集甲减与乳腺癌发生率的相关性研究。采用RevMan5.3软件进行 Meta分析。结果 共纳入12个研究，总样本量为 24571 例。Meta分析结果表明甲减患者发生乳腺癌的风险与甲状腺功能正常组差异不显著（OR=0.93，95% CI为 0.84~1.03，P=0.16）。结论 Meta分析结果显示甲减和乳腺癌发生之间无明显相关性。本研究结论仍需在开展大量高质量、长期随访的 RCT 下予以证实。

关键词： 乳腺癌；甲状腺功能减退；甲状腺激素；Meta分析

中图分类号： R737.9文献标志码：A文章编号：2096-1413(2018)07-0004-04

Meta analysis of relationship between hypothyroidism and breastcancer

FANG Yuan 1 ,LIYan-xia 2 ,ZHANG Jian 3 ,SUN Jing 3 ,TIAN Li-min 4*
(1.ClinicalMedicineAcademy,Gansu UniversityofChineseMedicine,Lanzhou 730000;2.UltrasonographyDepartment,
HebeiProvincialVeteransHospital,Baoding071000;3.ClinicalMedicalAcademy,NingxiaMedicalUniversity,Yinchuan
750004;4.EndocrinologyDepartment,Gansu ProvincialHospital,Lanzhou 730000,China)



ABSTRACT: Objective To systematically evaluate the relationship between hypothyroidism and breast cancer. Methods The PubMed,CNKIand CBM data bases were searched to identify researches that assessed the relationship between hypothyroidism and breast cancer, the reasearch deadline was  Octorber 2017, and Meta analysis was performed with RevMan 5.3 software. Results A total of 12 population-based studies including 24 571 participants were analyzed. The results of Meta analysis showed that the risk of breastcancerin hypothyroidism patients was not significantly different from that in objects with normal thyroid function (OR=0.93,95% CI:0.84-1.03,P=0.16).Conclusion Meta analysis illustrated  that hypothyroidism may not be related to the incidence of breast cancer.The conclusions of this study still need to be confirmed with alarge number of high-quality,long-term RCTs.
KEYWORDS:breast cancer;hypothyroidism;thyroid hormone; Meta analysis

参考文献：
[1]JEMAL A.Globalcancerstatistics[J].Ca A CancerJClin,2011,61(2):34.
[2] CHEN W ,ZHENG R.Incidence, mortality and survival analysis of breastcancerin China[J].Chinese JCliOncol,2015(13).
[3]BEATSON GT.On the treatmentofinoperable casesofcarcinoma of themammary.Suggestion fora new method with illustrative cases[J].Lancet,1989,148(3803):162-165.
[4] MAHBOULI S,DER AV,ORTEGA S,etal.Leptin induces ROS via NOX5 in healthy and neoplastic mammary epithelialcells[J].Oncol-ogyReports,2017,38(5):3254-3264.
[5]SZYCHTA P,SZYCHTA W ,GESING A,etal.TSH receptor antibodies have predictive value for breast cancer-retrospective analysis[J].Thyroid Res,2013,6(1):1-8.
[6] TOSOVIC A,BONDESON AG,BONDESON L,et al.Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in post men opausal women [J].Breast Cancer Res,2010,12(3): R33.                                                                                                                                  [7]SOGAARD M,FARKAS DK,EHRENSTEIN V,etal.Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study[J].EuroJendocrinol,2016,174(4):409-414.
[8] ANGELOUSI AG,ANAGNOSTOU VK,STAMATAKOS MK,et al.Mechanisms in endocrinology:primary HT and risk forbreastcan-cer: a systematic review and meta-analysis[J].Euro J Endocrinol,2012,166(3):373-381.
[9]YANG YL,LIU L,W ANG Y,etal.The prevalence ofdepression and anxiety among Chinese adults with cancer:a systematic review and meta-analysis [J].BMC Cancer,2013,13(1):393.
[10] CANFIELD SE,DAHM P.Rating the quality of evidence and the strength of recommendations using GRADE [J].W orld J Urology,2011,29(3):311-317.
[11]SIMON MS,TANG MT,BERNSTEIN L,etal.Do thyroid disorders in-crease the risk ofbreastcancer?[J].Cancer EpidemiolBiomarkersPrev,2002,11(12):1574-1578.
[12] GRANI G,DICORATO P,DAINELLI M,et al.Thyroid diseases in women with breastcancer[J].Clin Ter,2012,163(6):e401-404.
[13]DITSCH N,LIEBHARDT S,VON KF,etal.Thyroid function in breast cancer patients[J].AnticancerRes,2010,30(5):1713-1717.
[14] CRISTOFANILLI M,YAM AMURA Y,KAU SW ,et al.Thyroid hor-mone and breastcarcinoma.Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma[J].Cancer,2005,103(6):1122-1128.
[15]TURKEN O,NARIN Y,DEMIRBAS S,etal.Breastcancerin associ-ation with thyroid disorders[J].BreastCancer Res,2003,5(5):R110-113.
[16]TALAMINIR,FRANCESCHIS,FAVERO A,etal.Selected medical conditions and riskofbreastcancer[J].BriJCancer,1997,75(11):1699-1703.
[17]SMYTH PP,SMITH DF,MCDERMOTT EW ,etal.A directrelation-ship between thyroid enlargementand breastcancer[J].J CliEn-docrinolMetab,1996,81(3):937-941.
[18]SHERING SG,ZBAR AP,MORIARTY M,etal.Thyroid disorders and breastcancer[J].EurJCancerPrev,1996,5(6):504-506.
[19]MOSESON M,KOENIG KL,SHORE RE,etal.The influence ofmed-icalconditionsassociated with hormones on the risk of breastcan-cer[J].IntJEpidemiol,1993,22(6):1000-1009.
[20] BRINTON LA,HOFFMAN DA,HOOVER R,et al.Relationship of thyroid disease and use of thyroid supplements to breastcancerrisk[J].JChronicDis,1984,37(12):877-893.
[21]KALACHE A,VESSEY MP,MCPHERSON K.Thyroid disease and breastcancer:findings in a large case-controlstudy[J].BriJSurg,1982,69(7):434-435.
[22] ADAMI HO,RIMSTEN A,THOREN L,et al.Thyroid disease and function in breast cancer patientsand non-hospitalized controlse-valuated bydetermination ofTSH,T 3 ,rT 3 and T 4 levelsin serum[J].Acta ChirScand,1978,144(2):89-97.